Tweets
Join us for our daily topic panels--we'll be live on Twitter, LinkedIn, FB and YouTube OR sign up directly below.
https://t.co/lZK8vsySiD https://t.co/smUveqf3C6
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 8 months ago
What if my #myositis patient gets pregnant?
Abstract #0952 #ACR22 @RheumNow
🫁10 pregnancies ➡️ 1 miscarriage
-2 preterm
-3 low birth wght
-1 HELLP
-Mean gestational age 36w
🫁 Higher disease activity ➡️ more adverse pregnancy outcomes
Catherine Sims, MD @DrCassySims ( View Tweet )
3 years 8 months ago
Application of 2022 adult-based AAV ACR/EULAR classification criteria to a large cohort of pediatric vasculitis patients resulted in different classification of one-third of patients compared to the EMA classification algorithm. Abs 0456 #ACR22 @RheumNow https://t.co/AWk4RijJLP https://t.co/nX96xTf7KW
Dr. Rachel Tate @uptoTate ( View Tweet )
3 years 8 months ago
JAKi appear to be an effective and safety therapy in refractory GCA to cDMARDs and/or bDMARDs. Abs 0464 #ACR22 @RheumNow https://t.co/0ZjI8uTgnY https://t.co/OgxND7HrXj
Dr. Rachel Tate @uptoTate ( View Tweet )
3 years 8 months ago
Mortality increased by 50% in GCA pts compared to matched controls during first year of follow up after dx. Main cause of this early excess mortality appears to be CVD. Abs 0467 #ACR22 @RheumNow https://t.co/TEV0qSlJuQ https://t.co/U8gv2SXhdQ
Dr. Rachel Tate @uptoTate ( View Tweet )
3 years 8 months ago
Death rate is higher in the first year after AAV diagnosis and remains elevated in long-term follow up. Primary cause of death is the vasculitis itself. Abs 0448 #ACR22 @RheumNow https://t.co/z7qBnefTbR https://t.co/PRaUeK2XXd
Dr. Rachel Tate @uptoTate ( View Tweet )
3 years 8 months ago
@alberta_hoi @RheumNow @seminarthrheum Indeed! Thanks Alberta
I think:
- they're not as separate as some might think
- it's possible beta-blockers could prevent damage-related remodelling
- at the least, couldn't they be additive?
Whatever the case, if it's real I want to use it. Big signal needs testing? #ACR22
David Liew @drdavidliew ( View Tweet )
3 years 8 months ago
International survey finds induction therapy patterns for severe ANCA-associated vasculitis differ based on physician specialty, expertise, and practice setting. Abs 0442 #ACR22 @RheumNow https://t.co/gB6QhYnbp5 https://t.co/Io2hA9EZiW
Dr. Rachel Tate @uptoTate ( View Tweet )
3 years 8 months ago
🦵Heel enthesitis on physical exam predictive of ⬇️ likelihood of low disease activity and ⬆️ scores in Global VAS, BASDAI, ASDAS and BASFI on 2yr follow up in r-axSpA
# The Achilles heel of r-axSpA!
Abst#0375
#ACR22 @RheumNow
Patricia Harkins @DrTrishHarkins ( View Tweet )
3 years 8 months ago
@rheum_cat et al Abs 0415 TNFi initiation early in AS dz course (compared to no initiation) showed higher risk of incident CVD, stroke & MACE individually! Residual confounding by indication cannot be excluded. Were TNFi tx pts sicker? #ACR22 @RheumNow https://t.co/ERoDhS2yOY https://t.co/8tto5AIUSP
Dr. Rachel Tate @uptoTate ( View Tweet )
3 years 8 months ago
🤕 Late onset PsA associated with
⬆️ structural damage
💪🏻UL > LL arthritis
⬆️ BASFI
🙋♂️ males
⬇️ enthesitis/ sacroilitis
Abst# 0377
#ACR22 @RheumNow
Patricia Harkins @DrTrishHarkins ( View Tweet )
3 years 8 months ago
Can I use BASDAI to asses disease in #pregnant AS patients?
Abstract #0374 #ACR22 @RheumNow; 50 women
🫃Back pain and fatigue beyond 4.5 months = not reliable
🫃BASDAI in 3rd trimester = not reliable
🫃Morning stiffness remains reliable marker of disease in pregnancy
Catherine Sims, MD @DrCassySims ( View Tweet )
3 years 8 months ago
